11 September 2024
11 September 2024
Article doesn't exist
Data from the two Phase III trials showed that once-weekly insulin efsitora induced HbA1C reductions similar to daily insulin in both type 1 and type 2 diabetes.
Baltimore opted out of a national settlement last year, instead pursuing its own claim against the opioid manufacturer.
This research addresses the early identification of type 1 diabetes, celiac disease, and autoimmune thyroid disease using innovative antibody detection technologies.
The new biotech has inherited two T cell engager antibodies as part of a three-way merger with Vignette and TRC 2004.
The study, which analysed data from over 11,000 individuals across five major T1D cohorts, delivers evidence on maternal protection against T1D in children, compared to paternal transmission.
In trials, plozasiran has shown promising results by reducing triglycerides and other atherogenic lipoproteins.
The 24,000m² facility can reconfigure rapidly for the production of up to four different products simultaneously.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
